Search

Displaying results 4181 - 4190 of 5262 in total
  1. Drug

    BB-1701

    go.drugbank.com/drugs/DB17443
    Investigational

    BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

  2. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    It was developed by Sixal Inc.

  3. Drug

    Adelmidrol

    go.drugbank.com/drugs/DB16083
    Investigational

    Placebo for Gynecologic Oncology Patients Affected by Vaginitis).

  4. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...

  5. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  6. Drug

    TOL2

    go.drugbank.com/drugs/DB17918
    Experimental

    TOL2 is a modified form of the acetylcholine receptor being investigated for the treatment of myasthenia gravis.[A260117]

  7. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  8. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional

  9. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    It is being developed by AstraZeneca.

  10. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    It is being developed by Alkermes, Inc.